Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classification

Author:

Proud Crystal M.1,Mercuri Eugenio2,Finkel Richard S.3,Kirschner Janbernd4,De Vivo Darryl C.5,Muntoni Francesco67,Saito Kayoko8,Tizzano Eduardo F.9,Desguerre Isabelle10,Quijano‐Roy Susana11,Benguerba Kamal12,Raju Dheeraj13,Faulkner Eric131415,Servais Laurent1617ORCID

Affiliation:

1. Children's Hospital of The King's Daughters Norfolk Virginia USA

2. Department of Paediatric Neurology and Nemo Clinical Centre Catholic University Rome Italy

3. Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital Memphis Tennessee USA

4. Department of Neuropediatrics and Muscle Disorders Medical Center University of Freiburg, Faculty of Medicine Freiburg Germany

5. Departments of Neurology and Pediatrics Columbia University Irving Medical Center New York New York USA

6. The Dubowitz Neuromuscular Centre University College London, Great Ormond Street Institute of Child Health & Great Ormond Street Hospital London UK

7. National Institute of Health Research, Great Ormond Street Hospital Biomedical Research Centre London UK

8. Institute of Medical Genetics, Tokyo Women's Medical University Tokyo Japan

9. Department of Clinical and Molecular Genetics Hospital Vall d'Hebron Barcelona Spain

10. Hôpital Necker Enfants Malades, APHP Paris France

11. Garches Neuromuscular Reference Center (GNMH) APHP Raymond Poincare University Hospital (UVSQ Paris Saclay) Garches France

12. Novartis Gene Therapies Switzerland GmbH Rotkreuz Switzerland

13. Novartis Gene Therapies, Inc Bannockburn Illinois USA

14. Institute for Precision and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

15. Genomics, Biotech and Emerging Medical Technology Institute, National Association of Managed Care Physicians Richmond Virginia USA

16. Department of Paediatrics MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre University of Oxford Oxford UK

17. Department of Paediatrics, Neuromuscular Reference Center University and University Hospital of Liège Liège Belgium

Abstract

AbstractWe sought to devise a rational, systematic approach for defining/grouping survival motor neuron‐targeted disease‐modifying treatment (DMT) scenarios. The proposed classification is primarily based on a two‐part differentiation: initial DMT, and persistence/discontinuation of subsequent DMT(s). Treatment categories were identified: monotherapy add‐on, transient add‐on, combination with onasemnogene abeparvovec, bridging to onasemnogene abeparvovec, and switching to onasemnogene abeparvovec. We validated this approach by applying the classification to the 443 patients currently in the RESTORE registry and explored the demographics of these different groups of patients. This work forms the basis to explore the safety and efficacy profile of the different combinations of DMT in SMA.

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3